Skip to main content
. 2011 Jun;79(6):2324–2334. doi: 10.1128/IAI.01316-10

Fig. 8.

Fig. 8.

Strain conservation of mtrC and LL-37 and HBD-3 resistance in H. ducreyi clinical isolate 6644. (A) PCR amplification of the mtrC ORF from class I and class II clinical isolates of H. ducreyi. A 1.602-kbp fragment was amplified from genomic DNA of each strain using primers flanking the mtrC ORF in 35000HP. Lanes 1 to 6 contain class I strains 35000HP, HD183, HD188, 82-029362, 6644, and HD85-023233, respectively; lanes 7 to 10 contain class II strains CIP542 ATCC, HMC112, 33921, and DMC164, respectively. nt, no template control. (B and C) Survival of 35000HP and 6644 exposed to the indicated concentrations of LL-37 (B) or HBD-3 (C). The data represent the means and standard errors of five independent assays. The asterisks indicate significant differences from 35000HP (P ≤ 0.04). (D) Western blot of whole-cell lysates of 35000HP and 6644 probed with PAL-specific monoclonal antibody 3B9, as a loading control, and either DsrA-specific (top) or OmpP2B-specific (bottom) antibodies. The fold change in DsrA and OmpP2B expression compared to 35000HP, after normalization to PAL, is indicated at the bottom.